CWA Asset Management Group LLC Lowers Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

CWA Asset Management Group LLC lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,605 shares of the specialty pharmaceutical company’s stock after selling 2,088 shares during the period. CWA Asset Management Group LLC’s holdings in Jazz Pharmaceuticals were worth $3,276,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. Itau Unibanco Holding S.A. purchased a new stake in Jazz Pharmaceuticals in the second quarter worth about $29,000. EverSource Wealth Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 121 shares during the last quarter. Venturi Wealth Management LLC increased its position in Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after buying an additional 704 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 350 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $121.82 on Tuesday. The firm has a market capitalization of $7.36 billion, a P/E ratio of 17.16, a PEG ratio of 1.04 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17. The business has a fifty day moving average of $121.24 and a 200 day moving average of $113.79.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now owns 427,025 shares in the company, valued at $51,742,619.25. The trade was a 0.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,253 shares of company stock worth $1,001,434 in the last three months. 4.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent research reports. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, TD Cowen decreased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.